<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - TERIFLUNOMIDE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>TERIFLUNOMIDE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#treatmentCessation" data-toggle="tab">Treatment cessation</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of relapsing-remitting multiple sclerosis (initiated under specialist supervision)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                14 mg once daily.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Teriflunomide is a metabolite of leflunomide which has immunomodulating and anti-inflammatory properties.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Avoid&#8212;toxicity in animal studies.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Avoid in severe impairment.</p>
            </section>
      </section>


      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Anaemia</li>
            <li>leucopenia</li>
            <li>neutropenia</li>
            <li>serious infection</li>
            <li>severe hypoproteinaemia</li>
            <li>severe immunodeficiency</li>
            <li>significantly impaired bone-marrow function</li>
            <li>thrombocytopenia</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Acne, alopecia, anxiety, carpal tunnel syndrome, cystitis, diarrhoea, elevated liver enzymes, gastroenteritis, hyperaesthesia, hypertension, laryngitis, leucopenia, menorrhagia, musculoskeletal pain, myalgia, nausea, neuralgia, neutropenia, oral infection, paraesthesia, peripheral neuropathy, pollakiuria, rash, respiratory tract infection, sciatica, tinea pedis, urinary tract infection, vomiting, weight loss,
              </p>
              <p>
                <strong>uncommon:</strong> Anaemia, thrombocytopenia,
              </p>
              <p>
                <strong>veryRare:</strong> Interstitial lung disease, pancreatitis,
              </p>
        
        
            <section class="advice">
                <h3>Accelerated elimination procedure</h3>
              <p>
            <b>Important</b>: accelerated elimination procedure recommended following discontinuation due to serious adverse effects (consult product literature).</p>
            </section>
            <section class="advice">
                <h3>Hepatic injury</h3>
              <p>Discontinue treatment if signs or symptoms of hepatic injury, or if liver enzymes exceed 3 times the upper limit of reference range.</p>
            </section>
        
      </section>



      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA303</h3>
              <p outputclass="title">Teriflunomide for treating relapsing-remitting multiple sclerosis (January 2014)</p> <p>Teriflunomide is recommended for the treatment of adults with active relapsing-remitting multiple sclerosis (normally defined as 2 clinically significant relapses in the previous 2 years), in adults who:</p> <ul> <li>do not have highly active or rapidly evolving severe relapsing-remitting multiple sclerosis <b>and</b> </li> <li>the manufacturer provides teriflunomide with the discount agreed in the patient access scheme</li> </ul><xref format="html" href="http://www.nice.org.uk/TA303">www.nice.org.uk/TA303</xref>
                <a href="http://www.nice.org.uk/TA303" target="_blank">www.nice.org.uk/TA303</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Adult over 65 years
          </li>
          <li>
            anaemia
          </li>
          <li>
            dyspnoea&#8212;assess for interstitial lung disease and consider suspending treatment
          </li>
          <li>
            hypoproteinaemia (avoid if severe)
          </li>
          <li>
            impaired bone-marrow function (avoid if severe)
          </li>
          <li>
            latent tuberculosis
          </li>
          <li>
            leucopenia
          </li>
          <li>
            persistent cough&#8212;assess for interstitial lung disease and consider suspending treatment
          </li>
          <li>
            severe infection&#8212;delay or suspend treatment until resolved
          </li>
          <li>
            significant alcohol consumption
          </li>
          <li>
            signs or symptoms of serious skin reactions (including ulcerative stomatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis)&#8212;discontinue treatment
          </li>
          <li>
            switching between other immunomodulating drugs
          </li>
          <li>
            thrombocytopenia
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Effective contraception essential for women of child-bearing potential during treatment and for up to 2 years after treatment.</p>
            </section>
            <section class="generalInformation">
              <p>In patients undergoing treatment with teriflunomide that are planning to conceive, the accelerated elimination procedure should be used prior to conception. Use of non-oral contraception is recommended during the accelerated elimination procedure&#8212;consult product literature.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor full blood count (including differential white cell count and platelet count) before treatment and as clinically indicated during treatment.</p><p>Monitor blood pressure before treatment and periodically thereafter.</p>
            </section>
            <section class="patientParameters">
                <h3>Hepatic monitoring</h3>
              <p>Monitor liver function before treatment and every 2 weeks for first 6 months then every 8 weeks thereafter or as clinically indicated (pre-existing liver disease may increase risk). Increase to weekly monitoring if alanine aminotransferase (ALT) is 2&#8211;3 times the upper limit of reference range; discontinue treatment if signs or symptoms of hepatic injury, or if liver enzymes exceed 3 times the upper limit of reference range.</p>
            </section>
      </section>



      <section class="tab-pane" id="treatmentCessation">
        <h2>Advice regarding ceasing treatment</h2>

            <section class="treatmentCessation">
                <h3>Accelerated elimination procedures</h3>
              <p>To aid drug elimination in case of serious adverse effect or before conception, stop treatment and give <i>either</i>
            <xref format="dita" href="#PHP727" type="drug" namespace="/drugs/colestyramine">colestyramine</xref>
            <i>or</i>
            <xref format="dita" href="#PHP182" type="drug" namespace="/drugs/charcoal-activated">charcoal, activated</xref>. After the accelerated elimination procedure a plasma concentration of less than 20&#8239;micrograms/litre (measured on 2 occasions at least 14 days apart) and a waiting period of one and a half months are necessary before conception.</p>
            </section>
      </section>








      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of TERIFLUNOMIDE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP101311"><a href="../medicinalForm/PHP101311.html" data-target="#PHP101311" data-action="load">Tablet</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
